Seyedeh Tarlan Mirzohreh

Dr. Seyedeh Tarlan Mirzohreh

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
SMSeyedeh Tarlan Mirzohreh
Seyedeh Tarlan Mirzohreh
HSHanieh Safarpour
Hanieh Safarpour
APAbdol Sattar Pagheh
Abdol Sattar Pagheh
Berit BangouraBerit Bangoura
Berit Bangoura
Aleksandra BaracAleksandra Barac
Aleksandra Barac
Ehsan AhmadpourEhsan Ahmadpour
Ehsan Ahmadpour
Background: Malaria in human immunodeficiency virus (HIV)-positive patients is an ever-increasing global burden for human health. The present meta-analysis summarizes published literature on the prevalence of malaria infection in HIV-positive children, pregnant women and adults.Methods: This study followed the PRISMA guideline. The PubMed, Science Direct, Google Scholar, Scopus and Cochrane databases were searched for relevant entries published between 1 January 1983 and 1 March 2020. All peer-reviewed original papers evaluating the prevalence of malaria among HIV-positive patients were included. Incoherence and heterogeneity between studies were quantified by the I2index and Cochran’s Q test. Publication and population biases were assessed with funnel plots, and Egger’s regression asymmetry test.Results: A total of 106 studies were included in this systematic review. The average prevalence of malaria among HIV-positive children, HIV-positive pregnant women and HIV-positive adults was 39.4% (95% confidence interval [CI]: 26.6–52.9), 32.3% (95% CI = 26.3–38.6) and 27.3% (95% CI = 20.1–35.1), respectively. In adult patients with HIV, CD4+(cluster of differentiation 4) < 200 cells/µl and age < 40 years were associated with a significant increase in the odds of malaria infection (odds ratio [OR] = 1.5, 95% CI = 1.2–1.7 and OR = 1.1, 95% CI = 1–1.3, respectively). Antiretroviral therapy (ART) and being male were associated with a significant decrease in the chance of malaria infection in HIV-positive adults (OR = 0.8, 95% CI = 0.7–0.9 and OR = 0.2, 95% CI = 0.2–0.3, respectively). In pregnant women with HIV, CD4+count < 200 cells/µl was related to a higher risk for malaria infection (OR = 1.5, 95% CI = 1.1–1.9).Conclusions: This systematic review demonstrates that malaria infection is concerningly common among HIV-positive children, pregnant women and adults. Among HIV-positive adults, ART medication and being male were associated with a substantial decrease in infection with malaria. For pregnant women, CD4+count of < 200 cells/µl was a considerable risk factor for malaria infection.Graphical

24 July 2024 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
SMSeyedeh Tarlan Mirzohreh
Seyedeh Tarlan Mirzohreh
PPPadideh Panahi
Padideh Panahi
FHFariba Heidari
Fariba Heidari
Objectives: Polycystic ovary syndrome (PCOS) is a prevalent and complex endocrine disorder that affects women of reproductive age. It has significant implications for female endocrine function, reproductive health, and metabolic disturbances, including insulin resistance, impaired glucose tolerance, and dyslipidemia. Studies have shown that decreased heart rate variability (HRV), a marker of autonomic dysfunction, is associated with adverse cardiovascular events. Recent research has focused on investigating autonomic function in PCOS, and some studies have suggested altered autonomic drive in these patients. The aim of this systematic review and meta-analysis was to evaluate cardiac autonomic function by analyzing HRV in women with PCOS.Methods: This systematic review was prepared using PRISMA reporting guidelines. The databases searched were PubMed, Scopus, Web of Science, and Cochrane. Risk of Bias was assessed using ROBINS-I for non-RCTs. The GRADE approach was employed to evaluate the level of certainty in the evidence for each outcome. In order to identify the underlying cause of high heterogeneity, a subgroup analysis was conducted. Sensitivity analysis was checked. A random effect model was used and calculated a pooled standardized mean difference (SMD) with a 95% confidence interval (CI).Results: Seventeen articles were included in the final analysis, varied in quality, ranging from a "low" to a "high risk of bias". Combined analyses indicated a notable decrease in HRV among individuals with PCOS compared to the control group. Significant changes were observed in SDNN (SMD: -0.763, 95%CI [-1.289 to -0.237],p=0.004), PNN50 (SMD: -1.245, 95%CI [-2.07, -0.419],p=0.003), LF/HF ratio (SMD: 0.670, 95%CI [0.248, 1.091],p=0.002), HFnu (SMD: -0.873, 95%CI [-1.257, -0.489],p=0.000), LFnu (SMD: 0.840, 95%CI [0.428, 1.251],p=0.000) and TP (SMD: -1.997, 95%CI [-3.306, -0.687],p=0.003). The heterogeneity was partially explained by types of study design. Subgroup analysis revealed significant alterations of HRV in normal-weighted and overweight PCOS cases. Conversely, no significant changes in HRV were observed in obese PCOS cases.Conclusion: The findings of this meta-analysis provide evidence suggesting diminished HRV in individuals with PCOS compared to non-PCOS control group.

28 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
AAAlireza Azani
Alireza Azani
NANahal Aghajamal Avval
Nahal Aghajamal Avval
MMMohammad Saeed Soleimani Meigoli
Mohammad Saeed Soleimani Meigoli
MIMahshid Imankhan
Mahshid Imankhan
PAPouya Asgari
Pouya Asgari
MSMalihe Sharafi
Malihe Sharafi
Purpose This review investigates the complex association between type 2 diabetes mellitus (T2DM) and lung cancer, focusing on shared risk factors, molecular mechanisms, and clinical implications. We aim to quantify the impact of T2DM on lung cancer incidence, progression, and treatment response, and evaluate the role of glycemic control and antidiabetic therapies. Methods A narrative review was conducted following a targeted search of PubMed, Scopus, and Web of Science for published studies. Search terms included “type 2 diabetes mellitus,” “lung cancer,” “non-small cell lung cancer,” “hyperglycemia,” “insulin resistance,” and relevant synonyms. Inclusion criteria were original research articles, meta-analyses, and clinical trials involving human subjects that explored epidemiological associations, molecular mechanisms, pharmacologic interventions, or prognostic implications of T2DM in lung cancer. Studies focusing solely on type 1 diabetes, animal models, or non-English language were excluded. Key findings were synthesized to provide mechanistic insights and clinical relevance. Results Epidemiological evidence indicates a 20–48% increased relative risk of lung cancer in individuals with T2DM, with incidence rates reaching 125 per 100,000 in diabetics versus 85 per 100,000 in non-diabetics. Shared risk factors include obesity, smoking, and physical inactivity. Molecular pathways such as K-Ras and PI3K/Akt activation, IGF-1R overexpression, and hyperglycemia-induced oxidative stress promote tumorigenesis and metastasis. Metformin is associated with reduced lung cancer incidence and improved progression-free survival (58% vs. 37% at 2 years). Pioglitazone and DPP4 inhibitors show potential benefits, though clinical evidence remains mixed. Conclusion T2DM significantly influences lung cancer biology and prognosis. Integrating glycemic control with cancer therapy—particularly metformin and EGFR-TKI combinations—offers promising avenues for improving outcomes. Future research should focus on biomarker-driven stratification and targeted therapeutic strategies tailored to diabetic lung cancer patients.

23 May 2024 in Anatomical Science International
Verified
Journal Article
Closed access
PDF file
ASAliakbar Shoja
Aliakbar Shoja
MSMojtaba Sani
Mojtaba Sani
SMSeyedeh Tarlan Mirzohreh
Seyedeh Tarlan Mirzohreh
MEMohammad Javad Ebrahimi
Mohammad Javad Ebrahimi
MMMaral Moafi
Maral Moafi
POParia Davoudi Bavil Olyayi
Paria Davoudi Bavil Olyayi

6 May 2025 in Journal of Turkish Society of Obstetric and Gynecology
Verified
Journal Article
Open access
PDF file
SMSeyedeh Tarlan Mirzohreh
Seyedeh Tarlan Mirzohreh
AAArina Ansari
Arina Ansari
HPHana Piroti
Hana Piroti
RKReza Khademi
Reza Khademi
YJYalda Jahanbani
Yalda Jahanbani
PAParvin Bastani Alamdari
Parvin Bastani Alamdari
Polycystic ovary syndrome (PCOS), affecting 5-10% of reproductive-aged women, is linked to metabolic disturbances such as insulin resistance, obesity, and lipid imbalance, which may elevate cardiovascular disease (CVD) risk. The relationship between PCOS and clinical cardiovascular events remains unclear. This meta-analysis evaluates the association between PCOS and cardiovascular and cerebrovascular events, including myocardial infarction (MI), stroke, ischemic heart disease (IHD), and overall CVD. We conducted a systematic review and meta-analysis of observational cohort studies published up to August 2024. Studies investigating the association between PCOS and cardiovascular or cerebrovascular events were included. Hazard ratios (HR) were used to assess mortality risk, while odds ratios (OR) evaluated CVD incidence. Statistical analyses were performed using STATA software, with publication bias assessed via funnel plots. Nineteen cohort studies, involving 1,222,912 participants, were analyzed. Women with PCOS had a significantly higher risk of stroke [OR: 1.89, 95% confidence interval (CI): 1.22-2.55]. However, no significant associations were found between PCOS and overall CVD (HR: 1.80, 95% CI: 5.43-9.04), MI (HR: 2.68, 95% CI: 0.69-4.82), or IHD (HR: 2.68, 95% CI: 0.69-4.67). Additionally, there was no significant increase in cardiovascular or all-cause mortality. This meta-analysis highlights that women with PCOS are at an increased risk of stroke, but no conclusive evidence links PCOS to other cardiovascular outcomes or mortality. Clinicians should prioritize stroke prevention in this population. Further large-scale, long-term studies are needed to clarify the cardiovascular risks associated with PCOS.

20 February 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
SJSepide Javankiani
Sepide Javankiani
MKMasoud Khodarahmi
Masoud Khodarahmi
FYForoozan Yarahmadi
Foroozan Yarahmadi
SMSeyedeh Tarlan Mirzohreh
Seyedeh Tarlan Mirzohreh
SMSaman Soltani Moghadam
Saman Soltani Moghadam
QBQumars Behfar
Qumars Behfar
Prostate cancer (PCa) remains one of the most common cancers and the second leading cause of cancer-related morbidity in men worldwide. RNA-binding proteins (RBPs) have emerged as crucial regulators of gene expression via binding to RNAs and influencing their stability, localization, alternative splicing, and translation. Aberrant expression of RBPs causes various diseases, including cancer. Growing evidence has indicated that RBPs participate in PCa tumorigenesis, progression, and therapeutic resistance. Specifically, RBPs can regulate cancerous behaviors of the cells, including proliferation, apoptosis, migration, invasion, and metastasis. This review aims to provide a comprehensive overview of the biological functions of RBPs, as well as the mechanisms by which they contribute to PCa, highlighting their crucial role in regulating signaling pathways and AR signaling. Furthermore, we discuss the clinical applications of RBPs in PCa as both prognostic and diagnostic biomarkers, as well as their potential as therapeutic targets.